IGC — IGC Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $34.79m
- $33.73m
- $1.35m
Annual cashflow statement for IGC Pharma, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.32 | -8.81 | -15 | -11.5 | -13 |
| Depreciation | |||||
| Non-Cash Items | 1.55 | 0.827 | 4.37 | 3.01 | 5.27 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.06 | -3.29 | 2.54 | 0.794 | 1.89 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -8.68 | -10.8 | -7.46 | -7.05 | -5.2 |
| Capital Expenditures | -4.47 | -1.59 | -0.742 | -0.619 | -0.515 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -5.08 | 4.98 | 0 | 0.384 | 0.198 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -9.55 | 3.39 | -0.742 | -0.235 | -0.317 |
| Financing Cash Flow Items | — | — | — | — | 0.5 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.059 | 14.7 | 4.14 | 0.1 | 3.52 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -18.4 | 7.29 | -4.09 | -7.26 | -2 |